Antitumor DNA vaccination against the Sox2 transcription factor

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F14%3A00011028" target="_blank" >RIV/00023736:_____/14:00011028 - isvavai.cz</a>
Result on the web
<a href="http://www.spandidos-publications.com/ijo/45/1/139" target="_blank" >http://www.spandidos-publications.com/ijo/45/1/139</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3892/ijo.2014.2402" target="_blank" >10.3892/ijo.2014.2402</a>

Result language
angličtina
Original language name
Antitumor DNA vaccination against the Sox2 transcription factor
Original language description
As cancer stem cells (CSCs) are resistant to chemotherapy, radiotherapy and targeted molecular therapy, immunotherapy of tumors could be aimed at their elimination. Markers specific for CSCs have not been identified to date, but microarray analyses haveshown that CSCs and embryonic stem cells use similar transcriptional programs, thus suggesting the production of shared transcription factors. In this study, we developed an experimental DNA vaccine against the transcription factor Sox2 that is importantfor self-renewal of stem cells and is overexpressed in numerous human cancers.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—

Project
<a href="/en/project/NT11541" target="_blank" >NT11541: Development of vaccines against markers of cancer stem cells</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2014
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)